Back to top
more

Abeona Therapeutics (ABEO)

(Delayed Data from NSDQ)

$5.98 USD

5.98
683,832

+0.13 (2.22%)

Updated Sep 1, 2026 04:00 PM ET

After-Market: $5.90 -0.08 (-1.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) beat on earnings and sales in the first quarter of 2020. The company lifts net sales guidance for the full year.

Zacks Equity Research

Moving Average Crossover Alert: Abeona Therapeutics

by Zacks Equity Research

Abeona Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for April 28th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 28th

Zacks Equity Research

Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?

by Zacks Equity Research

On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.

Zacks Equity Research

Is a Beat in Store for Abeona (ABEO) This Earnings Season?

by Zacks Equity Research

Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.

Zacks Equity Research

Celldex (CLDX) Soars: Stock Adds 10% in Session

by Zacks Equity Research

Celldex (CLDX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Zacks Equity Research

ChromaDex (CDXC) Jumps: Stock Rises 7.7%

by Zacks Equity Research

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

Abeona's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.

Zacks Equity Research

Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.

Zacks Equity Research

Dynavax Technologies (DVAX) in Focus: Stock Moves 9.1% Higher

by Zacks Equity Research

Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.